After being activated, T lymphocytes must consume fuel for energy and biomaterials to sustain rapid proliferation and differentiation. As a consequence, waste is generated that must be managed.

GammaDelta Therapeutics has developed a pipeline of novel allogeneic cell therapies based on its Vδ1+ γδ T cell platforms for the treatment of solid tumors and beyond. Gamma delta (γδ) T ...

A study supported by ANRS MIE and conducted by teams at Inserm, the University of Bordeaux, and the CNRS (ImmunoConcEpT), ...

In the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma (HCC), a study in Frontiers of Medicine has identified a pivotal role for CD39 ...

CAR-T cell therapy involves some known side-effects called Cytokine Release Syndrome (CRS), Macrophage Activation Syndrome ...